Morgan Stanley’s Rosetta Genomics Ltd. ROSG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-390,930
| Closed | -$160K | – | 6951 |
|
|
2018
Q1 | $160K | Buy |
390,930
+14,700
| +4% | +$7.13K | ﹤0.01% | 5558 |
|
|
2017
Q4 | $209K | Buy |
376,230
+179,907
| +92% | +$141K | ﹤0.01% | 5392 |
|
|
2017
Q3 | $206K | Buy |
196,323
+34,121
| +21% | +$60.4K | ﹤0.01% | 5339 |
|
|
2017
Q2 | $381K | Buy |
162,202
+99,899
| +160% | +$222K | ﹤0.01% | 4974 |
|
|
2017
Q1 | $183K | Buy |
62,303
+24,439
| +65% | +$132K | ﹤0.01% | 5362 |
|
|
2016
Q4 | $190K | Buy |
37,864
+9,700
| +34% | +$74.2K | ﹤0.01% | 5376 |
|
|
2016
Q3 | $281K | Buy |
28,164
+3,666
| +15% | +$44.6K | ﹤0.01% | 4843 |
|
|
2016
Q2 | $338K | Buy |
24,498
+4,397
| +22% | +$62.6K | ﹤0.01% | 4651 |
|
|
2016
Q1 | $263K | Buy |
20,101
+11,550
| +135% | +$147K | ﹤0.01% | 4818 |
|
|
2015
Q4 | $126K | Buy |
8,551
+5,983
| +233% | +$129K | ﹤0.01% | 5292 |
|
|
2015
Q3 | $76K | Sell |
2,568
-2,138
| -45% | -$72.9K | ﹤0.01% | 5552 |
|
|
2015
Q2 | $192K | Sell |
4,706
-354
| -7% | -$15.1K | ﹤0.01% | 5267 |
|
|
2015
Q1 | $188K | Buy |
5,060
+4,410
| +678% | +$167K | ﹤0.01% | 5241 |
|
|
2014
Q4 | $18K | Sell |
650
-392
| -38% | -$12.7K | ﹤0.01% | 6085 |
|
|
2014
Q3 | $44K | Buy |
1,042
+217
| +26% | +$9.86K | ﹤0.01% | 5777 |
|
|
2014
Q2 | $42K | Buy |
825
+504
| +157% | +$25K | ﹤0.01% | 5824 |
|
|
2014
Q1 | $19K | Sell |
321
-517
| -62% | -$26.7K | ﹤0.01% | 5981 |
|
|
2013
Q4 | $29K | Buy |
+838
| New | +$29.1K | ﹤0.01% | 5789 |
|
Other funds holding ROSG
Morgan Stanley's ROSG Position: Q2 2018 in Review
Morgan Stanley sold out of Rosetta Genomics Ltd. (ROSG) in Q2 2018, closing a stake of 390,930 shares — an estimated $160K sold.
Morgan Stanley first reported a position in ROSG in Q4 2013 and held it in 18 quarters. The position peaked at $381K in Q2 2017. 2 funds tracked by Wall St. Rank hold ROSG as of Q2 2018.
- Morgan Stanley reported no remaining Rosetta Genomics Ltd. position as of Q2 2018 after selling out during the quarter.
- Morgan Stanley sold 390,930 Rosetta Genomics Ltd. shares in Q2 2018, an estimated $160K.
- Morgan Stanley first reported a position in Rosetta Genomics Ltd. in Q4 2013 and held it in 18 quarters.
- Morgan Stanley's Rosetta Genomics Ltd. position peaked at $381K in Q2 2017.
- 2 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q2 2018.
Based on Morgan Stanley's 13F filing for Q2 2018, filed 14 Aug 2018.